Although numerous investigations are focused on developing vaccines that induce protective humoral responses, fewer studies are aimed at developing vaccines that induce broad and robust T cell responses. In order to design a potent T cell based vaccine, two critical components are needed: the identity of specific T cell epitopes and an optimized vaccine formulation capable of delivering the antigens and the adjuvants simultaneously. Previously, we have identified and characterized HLA-A2 and A24 binding conserved epitopes and have characterized the feasibility of epitope based vaccine for dengue infection. Using these T cell epitopes and N acetyl glucosamine incorporated into a calcium phosphate nanoparticle (CaPNP) delivery system as the model, we studied efficacy of such CTL vaccine. The present disclosure describes such a CTL vaccine utilizing such combination.. Evaluating the immunogenicity of CaPNP/Dengue peptides formulation in-vitro and in-vivo in HLA-transgenic mice demonstrates that the CaPNP vaccine is immunologically relevant to induce T cellresponses against all four serotypes of dengue virus infection. This formulation is simple, has a low investment manufacturing process, and is stable at room temperature in a lyophilized form, further reducing the manufacturing time and costs. Further, the formulation is a candidate for the development of effective multi-serotype specific dengue virus vaccine to be used as prophylactic vaccine to prevent dengue infection in non-infected healthy individuals, and has the potential to be used as a therapeutic vaccine in already infected individuals, to minimize the antibody mediated complications caused by secondary infections.Selon l'invention, bien que de nombreuses recherches soient focalisées sur la mise au point de vaccins qui induisent des réponses humorales de protection, un nombre moindre d'études visent à mettre au point des vaccins qui induisent des réponses de lymphocytes T larges et robustes. Afin de concevoi
